REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Longevity Optimizer

Anti-Aging & Longevityadvanced
22
Share
Peptides

4

Avg Daily mcg

13,643

Level

advanced

Added

May 16, 2026

Overview

The Longevity Optimizer is a comprehensive, advanced-tier anti-aging protocol that targets the four major axes of biological aging: telomere attrition, mitochondrial decline, immune senescence, and extracellular matrix degradation. This four-peptide stack represents one of the most complete longevity interventions available, combining Epithalon for chromosomal maintenance, MOTS-c for mitochondrial optimization, Thymosin Alpha-1 for immune rejuvenation, and GHK-Cu for tissue remodeling and gene expression modulation. Epithalon at 10000mcg daily activates telomerase to maintain and potentially restore telomere length, directly addressing the Hayflick limit that constrains cellular replication capacity. MOTS-c at 5000mcg every other day is a mitochondria-derived peptide that enhances cellular energy metabolism, improves insulin sensitivity, activates AMPK pathways, and promotes metabolic homeostasis, effectively rejuvenating the cellular powerhouses that decline with age. Thymosin Alpha-1 at 1500mcg three times per week restores thymic function and T-cell diversity, combating the immunosenescence that leaves aging individuals vulnerable to infections and cancer. GHK-Cu at 500mcg daily is a naturally occurring copper-binding tripeptide that remodels damaged collagen, activates over 4,000 genes toward a healthier expression pattern, provides potent antioxidant activity, and supports skin, organ, and connective tissue integrity. The synergy across these four peptides is multiplicative: cells that maintain their telomeres, power their mitochondria efficiently, remain under competent immune surveillance, and exist within healthy extracellular matrix age far more slowly than those lacking any single component. Administer Epithalon and GHK-Cu in the morning. MOTS-c is best taken on non-consecutive days, ideally before physical activity to leverage its exercise-mimetic properties. Thymosin Alpha-1 should be administered on fixed days (e.g., Monday, Wednesday, Friday). This stack is designed for committed biohackers and advanced users over 35 who prioritize healthspan extension and biological age reversal. Users should establish baseline longevity biomarkers including telomere length, DNA methylation age (epigenetic clocks), inflammatory panels, and mitochondrial function tests. Research backing each component spans decades, from Khavinson longevity studies on Epithalon to recent MOTS-c metabolic research and extensive GHK-Cu gene expression data. Cycle 12-16 weeks with physician oversight.

Dosing Protocol

10,000 mcg

per dose

MOTS-c

Every other day

Read more about MOTS-c →

5,000 mcg

per dose

Thymosin Alpha-1

3 times per week

Read more about Thymosin Alpha-1 →

1,500 mcg

per dose

500 mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.